These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 31259768)

  • 1. Cluster headache-like symptoms during treatment with tenofovir disoproxil fumarate and emtricitabine.
    Citerne Q; Boyer L; Moreau E; Garon J; Gillet P; Petitpain N
    AIDS; 2019 Jul; 33(9):1535-1536. PubMed ID: 31259768
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet.
    Wang X; Nutland W; Brady M; Green I; Boffito M; McClure M
    Int J STD AIDS; 2019 Jul; 30(8):765-768. PubMed ID: 31072205
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.
    Nozza S; Poli A; Ripa M; Galli L; Chiappetta S; Spagnuolo V; Rovelli C; Lazzarin A; Castagna A; Tambussi G
    J Antimicrob Chemother; 2017 Feb; 72(2):632-633. PubMed ID: 27798217
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute Trigeminal Neuralgia Associated with Initiation of Emtricitabine/Tenofovir for HIV Pre-Exposure Prophylaxis.
    Van Slyke L; Scott M
    J Int Assoc Provid AIDS Care; 2018; 17():2325958218760846. PubMed ID: 29534653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
    Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
    Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emtricitabine/tenofovir alafenamide (Descovy) for HIV.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):100-1. PubMed ID: 27466750
    [No Abstract]   [Full Text] [Related]  

  • 7. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
    Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M; Vandekerckhove L; Ruane P; Yazdanpanah Y; Katlama C; Xu X; Rodgers A; East L; Wenning L; Rawlins S; Homony B; Sklar P; Nguyen BY; Leavitt R; Teppler H;
    Lancet HIV; 2017 Nov; 4(11):e486-e494. PubMed ID: 28918877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute Kidney Injury After Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine (Atripla) Overdose.
    Havenith T; Burger D; Visschers MJ; Schippers J; Oude Lashof A
    Ther Drug Monit; 2017 Apr; 39(2):91-92. PubMed ID: 28230617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men.
    McAllister JW; Towns JM; Mcnulty A; Pierce AB; Foster R; Richardson R; Carr A
    AIDS; 2017 Jun; 31(9):1291-1295. PubMed ID: 28301425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities.
    Girometti N; Jones R; Levy J; McCormack S; Sullivan A; Barber TJ
    AIDS; 2016 Aug; 30(13):2131-3. PubMed ID: 27219131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.
    Grant PM; Kitch D; McComsey GA; Tierney C; Ha B; Brown TT
    HIV Clin Trials; 2015; 16(2):66-71. PubMed ID: 25872972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Descovy Approved for HIV Prexposure Prophylaxis.
    Aschenbrenner DS
    Am J Nurs; 2020 Feb; 120(2):20. PubMed ID: 31977410
    [No Abstract]   [Full Text] [Related]  

  • 13. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
    Brunetta J; Moreno Guillén S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S
    Patient; 2015 Jun; 8(3):257-67. PubMed ID: 25808940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
    Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
    Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
    Kabbara WK; Ramadan WH
    J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
    Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
    Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
    HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Association between Antiretroviral Therapy and Drug-Induced Immune Thrombocytopenia Purpura.
    Howard MD; Sim S
    Acta Haematol; 2019; 141(3):199-200. PubMed ID: 30840965
    [No Abstract]   [Full Text] [Related]  

  • 19. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
    Winston A; Post FA; DeJesus E; Podzamczer D; Di Perri G; Estrada V; Raffi F; Ruane P; Peyrani P; Crofoot G; Mallon PWG; Castelli F; Yan M; Cox S; Das M; Cheng A; Rhee MS
    Lancet HIV; 2018 Apr; 5(4):e162-e171. PubMed ID: 29475804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
    Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.